DE602006019916D1 - Adenovirale expressionsvektoren mit einer expressionskassette im e1-bereich und einer inaktivierten e2b-polymerase - Google Patents

Adenovirale expressionsvektoren mit einer expressionskassette im e1-bereich und einer inaktivierten e2b-polymerase

Info

Publication number
DE602006019916D1
DE602006019916D1 DE602006019916T DE602006019916T DE602006019916D1 DE 602006019916 D1 DE602006019916 D1 DE 602006019916D1 DE 602006019916 T DE602006019916 T DE 602006019916T DE 602006019916 T DE602006019916 T DE 602006019916T DE 602006019916 D1 DE602006019916 D1 DE 602006019916D1
Authority
DE
Germany
Prior art keywords
inactivated
polymerase
area
adenoviral
expression vectors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006019916T
Other languages
English (en)
Inventor
Timothy T Mayall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Canji Inc
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canji Inc filed Critical Canji Inc
Publication of DE602006019916D1 publication Critical patent/DE602006019916D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/40—Vector systems having a special element relevant for transcription being an insulator
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE602006019916T 2005-12-12 2006-12-11 Adenovirale expressionsvektoren mit einer expressionskassette im e1-bereich und einer inaktivierten e2b-polymerase Active DE602006019916D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75001205P 2005-12-12 2005-12-12
PCT/US2006/046942 WO2007070392A2 (en) 2005-12-12 2006-12-11 Adenoviral expression vectors having an expression cassette in the e1 region and an inactivated e2b polymerase

Publications (1)

Publication Number Publication Date
DE602006019916D1 true DE602006019916D1 (de) 2011-03-10

Family

ID=38163429

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006019916T Active DE602006019916D1 (de) 2005-12-12 2006-12-11 Adenovirale expressionsvektoren mit einer expressionskassette im e1-bereich und einer inaktivierten e2b-polymerase

Country Status (8)

Country Link
US (2) US20070249043A1 (de)
EP (1) EP1974044B1 (de)
JP (2) JP5097714B2 (de)
AR (1) AR058330A1 (de)
AT (1) ATE497010T1 (de)
CA (1) CA2633087C (de)
DE (1) DE602006019916D1 (de)
WO (1) WO2007070392A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6392069B2 (en) * 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
JP4801594B2 (ja) * 2003-12-10 2011-10-26 カンジ，インコーポレイテッド インターフェロン耐性腫瘍の処置のための方法および組成物
WO2007134325A2 (en) * 2006-05-15 2007-11-22 Introgen Therapeutics, Inc. Methods and compositions for protein production using adenoviral vectors
ES2725450T3 (es) 2007-07-02 2019-09-24 Etubics Corp Métodos y composiciones para la producción de un vector adenoviral para su uso en vacunaciones múltiples
ES2337973B8 (es) * 2008-05-16 2011-07-21 Proyecto De Biomedicina Cima, S.L. Adenovirus auxiliares auto-inactivantes para la produccion de adenovirus recombinantes de alta capacidad.
KR20120052369A (ko) * 2009-07-31 2012-05-23 팍스박스, 인코포레이티드 아데노바이러스계 벡터
TWI545196B (zh) * 2011-05-25 2016-08-11 國立大學法人岡山大學 Ｒｅｉｃ表現腺病毒載體
US9056133B2 (en) * 2011-05-25 2015-06-16 Cti-S.A. Pharmaceutical kit and method for treating cancer
WO2013119371A2 (en) * 2012-02-10 2013-08-15 The Board Of Trustees Of The Leland Stanford Junior University Mini-intronic plasmid vectors
PT2830662T (pt) 2012-03-29 2018-11-29 Univ Columbia Métodos para tratamento de distúrbios de perda de pelo
WO2013152230A1 (en) 2012-04-04 2013-10-10 The Trustees Of Columbia University In The City Of New York Smooth muscle specific inhibition for anti-restenotic therapy
US10350306B2 (en) 2013-02-15 2019-07-16 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Methods and compositions for treating genetically linked diseases of the eye
AU2014216160B2 (en) * 2013-02-15 2017-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services AAV8 retinoschisin expression vector for treating X-linked retinoschisis
CA2908198A1 (en) 2013-04-18 2014-10-23 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2015069469A1 (en) 2013-11-05 2015-05-14 Clontech Laboratories, Inc. Dry transfection compositions and methods for making and using the same
CN106714826A (zh) 2014-09-07 2017-05-24 西莱克塔生物科技公司 用于减弱基因表达调节抗病毒转移载体免疫应答的方法和组合物
AU2016205215B2 (en) 2015-01-09 2021-03-11 Etubics Corporation Methods and compositions for combination immunotherapy
US11149087B2 (en) 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy
WO2017035232A1 (en) 2015-08-25 2017-03-02 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2017044807A2 (en) 2015-09-09 2017-03-16 The Trustees Of Columbia University In The City Of New York Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
US10188750B1 (en) 2015-10-23 2019-01-29 University Of South Florida Self-replicating cell selective gene delivery compositions, methods, and uses thereof
KR20180101540A (ko) * 2016-01-15 2018-09-12 이투빅스 코포레이션 T 세포 면역요법을 위한 방법 및 조성물
AU2017297610B2 (en) 2016-07-15 2020-03-12 Etubics Corporation Compositions and methods for alphavirus vaccination
CA3031806A1 (en) * 2016-07-25 2018-02-01 Ascend Biopharmaceuticals Ltd Methods of treating cancer
HRP20220406T1 (hr) 2016-08-08 2022-05-27 Aerase, Inc. Pripravci i metode za liječenje raka deplecijom arginina i imunoonkološkim sredstvima
KR20190104194A (ko) 2017-01-07 2019-09-06 셀렉타 바이오사이언시즈, 인크. 합성 나노담체에 커플링된 면역억제제의 패턴화된 투여
SG11201908280SA (en) 2017-03-30 2019-10-30 Univ Queensland "chimeric molecules and uses thereof"
CA3063735A1 (en) 2017-05-26 2018-11-29 Etubics Corporation Combination immunotherapies comprising il-15 superagonists
US11116827B2 (en) 2017-06-02 2021-09-14 Etubics Corporation Compositions and methods for tumor vaccination and immunotherapy involving HER antigens
MX2020003838A (es) 2017-10-13 2020-08-06 Selecta Biosciences Inc Metodos y composiciones para atenuar las respuestas de inmunoglobulina m del vector de transferencia antiviral.
CA3084801A1 (en) 2017-12-05 2019-06-13 Aerase, Inc. Method and composition for treating arginase 1 deficiency
AU2019225251A1 (en) 2018-02-26 2020-10-15 AnTolRx, Inc. Tolerogenic liposomes and methods of use thereof
MX2021013163A (es) 2019-04-28 2022-02-21 Selecta Biosciences Inc Métodos para el tratamiento de sujetos con inmunidad preexistente a vectores de transferencia viral.
MX2021014566A (es) 2019-05-28 2022-03-22 Selecta Biosciences Inc Métodos y composiciones para la respuesta inmune atenuada anti-vector de transferencia viral.
WO2023064367A1 (en) 2021-10-12 2023-04-20 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2023172624A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835557B1 (en) * 1980-01-08 2004-12-28 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing human interferon-like polypeptides
TW442569B (en) * 1993-10-25 2001-06-23 Canji Inc Recombinant adenoviral vector
US6210939B1 (en) * 1993-10-25 2001-04-03 Canji, Inc. Recombinant adenoviral vector and methods of use
NL1000332C1 (nl) * 1994-08-31 1996-03-04 Victor Smit Graduele chemische modificatie van biologisch actieve peptiden en eiwitten.
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
DE69638058D1 (de) * 1995-06-15 2009-11-26 Crucell Holland Bv Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie
US6392069B2 (en) * 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
CA2177085C (en) * 1996-04-26 2007-08-14 National Research Council Of Canada Adenovirus e1-complementing cell lines
US6248514B1 (en) * 1996-07-09 2001-06-19 Canji, Inc. Methods for measuring viral infectivity
US6261823B1 (en) * 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
US6544769B1 (en) * 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
US6146891A (en) * 1997-01-31 2000-11-14 Schering Corporation Methods for cultivating cells and propagating viruses
ES2272053T3 (es) 1998-02-17 2007-04-16 Schering Corporation Composiciones que comprenden virus y metodos para concentrar preparaciones de virus.
US6670188B1 (en) * 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5994134A (en) * 1998-05-04 1999-11-30 Canji, Inc. Viral production process
US7691370B2 (en) 1998-10-15 2010-04-06 Canji, Inc. Selectivity replicating viral vector
US6649158B1 (en) * 1998-10-15 2003-11-18 Canji, Inc. Methods and compositions to induce antitumor response
US7001770B1 (en) * 1998-10-15 2006-02-21 Canji, Inc. Calpain inhibitors and their applications
US6430595B1 (en) * 1999-05-20 2002-08-06 Cisco Technology, Inc. Method and apparatus for establishing a database used for correlating information gathered via SNMP
US20020064860A1 (en) * 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
WO2004108088A2 (en) 2003-06-04 2004-12-16 Canji, Inc. Methods and compositions for interferon therapy
US7026164B2 (en) * 2003-07-03 2006-04-11 Cell Genesys, Inc. Adenovirus packaging cell lines
JP4801594B2 (ja) * 2003-12-10 2011-10-26 カンジ，インコーポレイテッド インターフェロン耐性腫瘍の処置のための方法および組成物
ATE516343T1 (de) 2004-12-13 2011-07-15 Canji Inc Zellinien zur produktion von replikationsdefektem adenovirus

Also Published As

Publication number Publication date
JP2009519038A (ja) 2009-05-14
US8398968B2 (en) 2013-03-19
JP2012016359A (ja) 2012-01-26
US20070249043A1 (en) 2007-10-25
US20100008889A1 (en) 2010-01-14
EP1974044B1 (de) 2011-01-26
CA2633087A1 (en) 2007-06-21
AR058330A1 (es) 2008-01-30
WO2007070392A2 (en) 2007-06-21
ATE497010T1 (de) 2011-02-15
CA2633087C (en) 2014-12-02
JP5097714B2 (ja) 2012-12-12
EP1974044A2 (de) 2008-10-01
WO2007070392A3 (en) 2008-04-10

Similar Documents

Publication Publication Date Title
DE602006019916D1 (de) Adenovirale expressionsvektoren mit einer expressionskassette im e1-bereich und einer inaktivierten e2b-polymerase
DE502006004030D1 (de) Abstands- und geschwindigkeitsregler mit stauerkennung
EP2158609A4 (de) Oxidhalbleiter und dünnfilmtransistoren damit
DE602006018707D1 (de) Borat und material, das strahlung im nahen infrarotbereich absorbiert
BRPI0807481A2 (pt) Corpo moldado transparente e artigo que evita reflexão que usa o mesmo
DK1700070T3 (da) Forbedringer i eller i forbindelse med tætninger
DE602006018906D1 (de) Haftklebemittel, haftklebefolie und oberflächenschutzfilm
DE602006010128D1 (de) Bestimmung der Detektionsreihenfolge in MIMO-Systemen mit adaptiver Modulation und Ablaufsterminierungsverfahren
DE602006019937D1 (de) Host-Gerät und denselben benutzendes Informationsverarbeitungssystem
BRPI0923507A2 (pt) motor e dispositivo elétrico que usa o mesmo.
NO20053140L (no) Ror med kanal i rorveggen.
GB0607291D0 (en) Computing with both lock-step and free-step processor modes
DE602005022926D1 (de) Wärmeerhöhung bei kritischem sichtbereich von transparenter kunststofftafel
BRPI0811021A2 (pt) Peptídeos e vacinas de tem8 compreendendo os mesmos
FI20040492A0 (fi) Viestinkäsittely
DE602007006093D1 (de) Umkehrbares wärmeempfindliches Färbematerial und umkehrbares wärmeempfindliches Aufzeichnungsmaterial, das dieses verwendet
DK2012816T3 (da) Anvendelse af Thymosin 1, alene eller i kombination med PTX3 eller Ganciclovir, til behandling af Cytomegalovirus infektion.
ITRM20040166A1 (it) Ceppi batterici lab con proprieta' probiotiche e composizioni che contengono gli stessi.
ITMI20050504A1 (it) Sensore con mrzzi di azionamento e di rilevazione integrati
BRPI0923402A2 (pt) Peptídeos c10rf59 e vacinas incluindo os mesmos.
FI20055684A (fi) Menetelmä taajuusmuuttajan yhteydessä ja taajuusmuuttaja
BRPI0816488A2 (pt) Pigmento, e, substrato para o mesmo
BRPI0810901A2 (pt) Cúpula de ventilador e acionamento
DE602004010875D1 (de) Lüfter und Kühlschrank mit demselben
FIU20050316U0 (fi) Työpisteasema ja laitteisto työpisteaseman yhteydessä